New light therapy combo aims to slow Alzheimer's

NCT ID NCT06992804

Recruiting now Disease control Sponsor: Xuanwu Hospital, Beijing Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This early-phase trial is testing whether combining near-infrared light therapy with the drug lecanemab can improve cognitive function in people with mild Alzheimer's disease. Twenty participants will be randomly assigned to receive either real light therapy plus lecanemab or a sham light therapy plus lecanemab for 16 weeks, followed by an open-label extension where everyone gets the real light therapy for up to 48 weeks. The study focuses on safety and changes in cognitive scores.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: near-infrared light therapy and lecanemab
What this could lead to: If it works, this could point toward a new combination treatment that slows cognitive decline in mild Alzheimer's disease.
What could go wrong: This is a very early, small trial with only 20 participants. The results may not be conclusive, and the treatment could have side effects or no benefit over lecanemab alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ALZHEIMER DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Alzheimer disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ALZHEIMER DISEASE

Contacts and locations

Locations

Xuanwu Hospital, Capital Medical University
RECRUITING

Beijing, 100053, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.